# Samsung Bioepis: replacing an ophthalmology channel tests the portability of commercial rights

The Harrow agreement reallocates US commercialization after a prior partner's exit while retaining Korean development and supply.

Canonical: https://kgcf.dsmlholdings.com/insights/samsung-bioepis-harrow-ophthalmology-rights-agreement/
Published: 2026-10-08
Author: [DSML Holdings LLC](https://www.dsmlholdings.com/)

Company: Samsung Bioepis
Event: 2025-07-17
Harrow's dated Form 8-K and joint announcement of the development and commercialization agreement.

## Reported metrics

- Agreement portfolio scope: Two products. BYOOVIZ and OPUVIZ US rights; not two separate transactions or proof of simultaneous launch.. [Source 1](https://www.sec.gov/Archives/edgar/data/1360214/000164117225019976/form8-k.htm)

## Reported evidence

Harrow's July 17, 2025 Form 8-K reports a development and commercialization agreement with Samsung Bioepis for BYOOVIZ and OPUVIZ in the United States. Bioepis would develop, manufacture and supply after commercial rights transitioned back from Biogen. The filing describes an upfront payment, conditional net-sales milestones and a share of US net sales, without disclosed amounts or rates. Harrow's July 1, 2026 release confirms its BYOOVIZ launch. That later channel launch is not represented as the product's first-ever US launch or as evidence that both products launched together.

## Investment interpretation

The case shows that a licensed product's distribution relationship can change independently of its scientific or regulatory foundation. The Korean developer preserves an opportunity by recovering and reallocating commercial rights, but the transition carries operational and timing risk. The economic asset is the ability to continue supplying through a viable channel on enforceable terms, not merely the existence of approval or a recognizable partner name.

## Economic assessment

The disclosed consideration has three distinct channels: upfront payment, conditional milestones and a share of net sales. Their amounts and settlement evidence are not provided, so they cannot be converted into a realized return. Transition spending and supply readiness may occur before steady receipts from the new partner. Net-sales definitions, inventory migration and responsibility for the prior channel's obligations determine whether the replacement improves retained contribution or simply restores an interrupted commercial route.

## Commercial Rights Must Be Transferable In Practice

A right that reverts after a partner exits can preserve value, but the operational transition requires more than a signed replacement agreement. Product information, ordering systems, support contacts and stock must move into a usable new channel. The developer's ability to preserve supply and customer confidence during that interval affects the value of its recovered rights. Legal reversion and a functioning market route should therefore be treated as related but separate achievements.

The announcement identifies the intended transition from Biogen back to Bioepis before Harrow assumes the commercial role. That dependency matters to the schedule. It does not support an assumption that the replacement partner immediately controls every commercial function on signing. A financing plan needs to identify which costs continue during transition, what receipts remain from the old route and who is responsible for obligations that outlast the prior agreement.

1. [Harrow / complete Form 8-K describing Bioepis agreement and payment structure](https://www.sec.gov/Archives/edgar/data/1360214/000164117225019976/form8-k.htm)
2. [Samsung Bioepis / joint agreement announcement](https://www.samsungbioepis.com/en/newsroom/newsroomView.do?currentPage=1&idx=484)

## Different Consideration Has Different Reliability

An upfront payment is not the same economic claim as a milestone tied to future net sales. A net-sales share then depends on actual commercial performance and contractual deductions. The complete filing is informative because it separates those forms of consideration, yet it does not disclose their numerical terms. A researcher should not estimate the upfront amount from an unrelated portfolio transaction or treat every possible milestone as current receivables.

For credit purposes, settlement status and enforceability matter as much as the nominal payment category. An invoiced or received payment can support a liquidity assessment; a sales target depends on the new channel's ability to generate and report demand. Audit rights and definitions of net sales determine the quality of the recurring claim. These questions can be assessed without inventing a royalty percentage or a guaranteed minimum volume absent from the public record.

1. [Harrow / complete Form 8-K describing Bioepis agreement and payment structure](https://www.sec.gov/Archives/edgar/data/1360214/000164117225019976/form8-k.htm)

## A Focused Channel Can Be Economically Useful

Harrow's later launch places BYOOVIZ within a specialist ophthalmology offering. That can provide operational advantages through familiarity with retina practices and their ordering needs. The potential value is not necessarily a larger organization, but a more relevant route to use. The release's description of its commercial network is issuer evidence and should not be mistaken for independently measured superiority over the prior channel.

A specialized partner still needs adequate inventory, support and payer coordination. Practices using administered medicines may consider both clinical suitability and the economics of buying and billing for treatment. A supplier can improve product availability while demand remains sensitive to reimbursement and alternative therapies. The developer's retained net contribution therefore depends on channel quality and payment terms together, not on the partner's sector focus alone.

3. [Harrow / later BYOOVIZ commercial launch through the new channel](https://investors.harrow.com/news-releases/news-release-details/harrow-announces-commercial-launch-byoovizr-united-states/)

## Follow-Through Is Product-Specific

The July 2026 evidence confirms Harrow's BYOOVIZ launch. It does not establish that OPUVIZ entered the market on the same date or that either product produced a particular sales amount. The original two-product agreement and the observed one-product launch should remain separate units of evidence. This is especially important when portfolio language encourages analysts to treat all contracted products as equally mature commercial assets.

The interval also illustrates why rights transitions deserve their own working-capital assessment. Manufacturing and support may need to be maintained while the commercial system is rebuilt. A developer with well-documented reversion and replacement rights can preserve strategic flexibility, but flexibility has a carrying cost. The case supports analysis of continuity and contract design, not an assertion that partner replacement automatically increases value or that the new channel's early activity has already converted into collected Korean profit.

2. [Samsung Bioepis / joint agreement announcement](https://www.samsungbioepis.com/en/newsroom/newsroomView.do?currentPage=1&idx=484)
3. [Harrow / later BYOOVIZ commercial launch through the new channel](https://investors.harrow.com/news-releases/news-release-details/harrow-announces-commercial-launch-byoovizr-united-states/)

## China - DSML comparison

Chinese ophthalmic biosimilars offer a competition comparison. The Harrow agreement does not cover a reported Chinese transaction.

## Japan - DSML comparison

Japanese commercialization rights must be reviewed separately; the cited agreement concerns US rights.

## Other Asia - Reported connection

Samsung Bioepis is the Korean developer and supplier retaining technical responsibilities.

## United States - Reported connection

The filing allocates US commercialization to Harrow following rights transition, with later BYOOVIZ launch evidence.

## Europe - DSML comparison

European channels are outside the specified US agreement. No new European rights transfer or receipt is inferred.

## Counterpoint

A specialist distributor may create a better route to customers, and reversion rights can protect the developer's ability to continue commercialization after a partner changes strategy. The countervailing risk is a costly transition with uncertain uptake and conditional consideration. Scientific quality alone cannot make the replacement channel immediately productive.

## Underwriting questions

1. What upfront consideration has actually settled, and what milestones remain conditional?

2. Which inventory, liabilities and support obligations transferred from the prior channel?

3. What product-specific demand and net-sales reporting support the new recurring claim?

## Primary sources

1. [Harrow / complete Form 8-K describing Bioepis agreement and payment structure](https://www.sec.gov/Archives/edgar/data/1360214/000164117225019976/form8-k.htm) (2025-07-17)

2. [Samsung Bioepis / joint agreement announcement](https://www.samsungbioepis.com/en/newsroom/newsroomView.do?currentPage=1&idx=484) (2025-07-17)

3. [Harrow / later BYOOVIZ commercial launch through the new channel](https://investors.harrow.com/news-releases/news-release-details/harrow-announces-commercial-launch-byoovizr-united-states/) (2026-07-01)